Laboratory for Drug Target Research, Department of Agriculture, Graduate School of Science and Technology, Shinshu University, 8304 Minami-Minowa, Kami-Ina, Nagano, 399-4598, Japan.
Laboratory for Epigenetics Drug Discovery, RIKEN Center for Biosystems Dynamics Research, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.
Eur J Med Chem. 2022 Jan 5;227:113948. doi: 10.1016/j.ejmech.2021.113948. Epub 2021 Oct 28.
DYRK1A phosphorylates proteins involved in neurological disorders in an intermolecular manner. Meanwhile, during the protein folding process of DYRK1A, a transitional folding intermediate catalyzes the intramolecular autophosphorylation required for the "one-off" inceptive activation and stabilization. In our previous study, a small molecule termed FINDY (1) was identified, which inhibits the folding intermediate-catalyzed intramolecular autophosphorylation of DYRK1A but not the folded state-catalyzed intermolecular phosphorylation. However, the structural features of FINDY (1) responsible for this intermediate-selective inhibition remain elusive. In this study, structural derivatives of FINDY (1) were designed and synthesized according to its predicted binding mode in the ATP pocket of DYRK1A. Quantitative structure-activity relationship (QSAR) of the derivatives revealed that the selectivity against the folding intermediate is determined by steric hindrance between the bulky hydrophobic moiety of the derivatives and the entrance to the pocket. In addition, a potent derivative 3 was identified, which inhibited the folding intermediate more strongly than FINDY (1); it was designated as dp-FINDY. Although dp-FINDY (3) did not inhibit the folded state, as well as FINDY (1), it inhibited the intramolecular autophosphorylation of DYRK1A in an in vitro cell-free protein synthesis assay. Furthermore, dp-FINDY (3) destabilized endogenous DYRK1A in HEK293 cells. This study provides structural insights into the folding intermediate-selective inhibition of DYRK1A and expands the chemical options for the design of a kinase inhibitor.
DYRK1A 通过分子间方式磷酸化涉及神经紊乱的蛋白质。同时,在 DYRK1A 的蛋白质折叠过程中,一个过渡态折叠中间体能催化“一次性”起始激活和稳定所需的分子内自动磷酸化。在我们之前的研究中,鉴定出一种小分子,称为 FINDY(1),它抑制折叠中间态催化的 DYRK1A 分子内自动磷酸化,但不抑制折叠状态催化的分子间磷酸化。然而,负责这种中间态选择性抑制的 FINDY(1)的结构特征仍然难以捉摸。在这项研究中,根据 FINDY(1)在 DYRK1A 的 ATP 口袋中的预测结合模式设计并合成了其结构衍生物。衍生物的定量构效关系(QSAR)表明,对折叠中间态的选择性取决于衍生物的大体积疏水性部分与口袋入口之间的空间位阻。此外,鉴定出一种有效的衍生物 3,其对折叠中间态的抑制作用强于 FINDY(1);它被命名为 dp-FINDY。虽然 dp-FINDY(3)与 FINDY(1)一样,不能抑制折叠状态,但它能在体外无细胞蛋白合成测定中抑制 DYRK1A 的分子内自动磷酸化。此外,dp-FINDY(3)使内源性 DYRK1A 在 HEK293 细胞中不稳定。这项研究为 DYRK1A 的折叠中间态选择性抑制提供了结构见解,并为设计激酶抑制剂扩展了化学选择。